
    
      To assess the efficacy and safety of cabergoline in reducing cocaine use in subjects with
      cocaine dependence. This is a DB, placebo-controlled, parallel group design study where
      subjects will receive either .5mg cabergoline or placebo for 12 weeks with a 4 week
      follow-up.
    
  